Medivir AB
MEDI.STDrugs in Pipeline
5
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Acyclovir in ME-609 vehicle (5% acyclovir)
Herpes Labialis
ME-609
Herpes Labialis
MIV-818 (fostroxacitabine bralpamide) + pembrolizumab
Hepatocellular Carcinoma
MIV-711
Osteoarthritis, Knee
Remetinostat
Skin Basal Cell Carcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Acyclovir in ME-609 vehicle (5% acyclovir) | Phase 3 | Herpes Labialis | - | - |
ME-609 | Phase 3 | Herpes Labialis | - | - |
MIV-818 (fostroxacitabine bralpamide) + pembrolizumab | Phase 2 | Hepatocellular Carcinoma | - | - |
MIV-711 | Phase 2 | Osteoarthritis, Knee | - | - |
Remetinostat | Phase 2 | Skin Basal Cell Carcinoma | - | - |
Frequently asked questions
What is in Medivir AB's drug pipeline?→
CatalystAlert tracks 5 drug candidates in Medivir AB's (MEDI.ST) pipeline across Phase 3, Phase 2. Its lead program is Acyclovir in ME-609 vehicle (5% acyclovir) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Medivir AB's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Medivir AB (MEDI.ST) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track MEDI.ST biotech catalysts?→
Add MEDI.ST to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Medivir AB's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.